Clinical Trial Detail

NCT ID NCT02785952
Title Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Southwest Oncology Group
Indications

lung squamous cell carcinoma

Therapies

Nivolumab

Ipilimumab + Nivolumab

Age Groups: adult

No variant requirements are available.